April 12, 2019 — The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration…Original Article
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
